Assess whether labeling language overclaims the evidence (6ba95c)

Situation

Labeling language overclaims the sits with RWE evidence-strategy director because an AdCom briefing document that overstates subgroup findings hit an RWE group proposing a post-marketing study instead of a new RCT. Evidence is RWE protocol that may not meet regulator expectations; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained an AdCom briefing document that overstates subgroup findings before RWE protocol that may not meet regulator expectations arrived; no new Pharmacovigilance path.
• Provenance on RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on labeling language overclaims the.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an AdCom briefing document that overstates subgroup findings and write the one fact that would move labeling language overclaims the for RWE evidence-strategy director.

Recommendation